The Centre hospitalier universitaire de Sherbrooke is the public healthcare network in Sherbrooke, Quebec, Canada, affiliated with the Université de Sherbrooke Faculty of Medecine.

There are 690 beds in Centre hospitalier universitaire de Sherbrooke.

During the past decade, Centre hospitalier universitaire de Sherbrooke conducted 186 clinical trials. In the 10-year time frame, 186 clinical trials started and 71 clinical trials were completed, i.e. on average, 38.2% percent of trials that started reached the finish line to date. In the past 5 years, 82 clinical trials started and 44 clinical trials were completed. i.e. 53.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre hospitalier universitaire de Sherbrooke" #1 sponsor was "Université de Sherbrooke" with 64 trials, followed by "NCIC Clinical Trials Group" with 19 trials sponsored, "Canadian Cancer Trials Group" with 18 trials sponsored, "Centre de recherche du Centre hospitalier universitaire de Sherbrooke" with 16 trials sponsored and "Hoffmann-La Roche" with 16 trials sponsored. Other sponsors include 187 different institutions and companies that sponsored additional 116 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre hospitalier universitaire de Sherbrooke" #1 collaborator was "National Cancer Institute (NCI)" with 34 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 32 trials as a collaborator, "Centre de recherche du Centre hospitalier universitaire de Sherbrooke" with 12 trials as a collaborator, "SWOG Cancer Research Network" with 8 trials as a collaborator and "AstraZeneca" with 7 trials as a collaborator. Other collaborators include 337 different institutions and companies that were collaborators in the rest 209 trials.

According to Clinical.Site data, the most researched conditions in "Centre hospitalier universitaire de Sherbrooke" are "Breast Cancer" (12 trials), "Atrial Fibrillation" (9 trials), "Prostate Cancer" (9 trials), "Fallopian Tube Cancer" (6 trials) and "Obesity" (6 trials). Many other conditions were trialed in "Centre hospitalier universitaire de Sherbrooke" in a lesser frequency.

Most popular intervention types in "Centre hospitalier universitaire de Sherbrooke" are "Drug" (163 trials), "Other" (67 trials), "Procedure" (38 trials), "Biological" (37 trials) and "Radiation" (37 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (34 trials), "Cyclophosphamide" (11 trials), "Dexamethasone" (8 trials), "Pembrolizumab" (8 trials) and "Paclitaxel" (7 trials). Other intervention names were less common.

The vast majority of trials in "Centre hospitalier universitaire de Sherbrooke" are 242 trials for "All" genders, 55 trials for "Female" genders and 21 trials for "Male" genders.

Currently, there are 125 active trials in "Centre hospitalier universitaire de Sherbrooke". 3 are not yet recruiting, 61 are recruiting, 59 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 141 completed trials in Centre hospitalier universitaire de Sherbrooke, 1 suspended trials, and 24 terminated clinical trials to date.

Out of the total trials that were conducted in Centre hospitalier universitaire de Sherbrooke, 3 "Phase 1" clinical trials were conducted, 57 "Phase 2" clinical trials and 126 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 18 trials, and there were also 71 trials that are defined as “Not Applicable".

Centre hospitalier universitaire de Sherbrooke has several departments that took part in Clinical trials: "Service Radio-Oncologie, Chus" - 2 trials